By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sunovion Pharmaceuticals Inc. 

84 Waterford Drive

Marlborough  Massachusetts  01752  U.S.A.
Phone: 508-481-6700 Fax:



Acadia  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.


Company News
Demi Lovato, Sunovion And Leading Advocacy Organizations Release Mental Health Documentary As Part Of Be Vocal Initiative 2/22/2017 6:19:14 AM
Sunovion’s Latuda (lurasidone HCl) Receives FDA Approval To Treat Adolescents With Schizophrenia 1/30/2017 9:53:02 AM
Sunovion Release: Biopharma Announces Pivotal Study Results For Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms In Children Compared To Placebo 1/16/2017 7:05:58 AM
Sunovion Release: Massachusetts Biotech Touts Binge Eating and ADHD Mid-Stage Trials Data 1/13/2017 7:10:48 AM
Sunovion Enters Into License Agreement For Three Approved Treatment Options For People With COPD In The U.S. 12/21/2016 12:41:47 PM
Sunovion Announces Collaboration With AMDA – The Society For Post-Acute And Long-Term Care Medicine 12/15/2016 8:14:26 AM
Sunovion Initiates SEP-363856 Phase II Program For Patients With Schizophrenia Or Parkinson’s Disease Psychosis 12/2/2016 7:44:28 AM
Demi Lovato, Sunovion And Leading Advocacy Organizations Launch The Be Vocal Collection In Partnership With Getty Images To Encourage The Realistic Portrayal Of Mental Health 11/30/2016 10:20:26 AM
Sunovion Recognizes Epilepsy And COPD Awareness Months In The U.S. During November 11/1/2016 12:30:16 PM
Sunovion Announces Positive Clinical Study Results For Latuda (Lurasidone HCL) In Adolescents With Schizophrenia 10/27/2016 11:29:40 AM